Komori
ASKA Pharmaceutical Holdings (4886) · InitiativeAdvanced

Establishment of Group Nomination and Group Compensation Committees

First written in FY2023. 4 of 5 entries say "Advanced", first in FY2024. Latest entry: FY2026.

5entries
4years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2023AdvancedFY2024 – FY20262023: 120232024: 120242025: 120252026: 22026
Same theme, other companies
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 198 companies compared. The sentences above are computed from all 198.Comparing 200 of the theme's 679 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「2025年度は、監査等委員会設置会社への移行を見据えた機関設計変更後の取締役候補者や、サクセッションプラン等について審議を行い、取締役会への答申内容を決定いたしました。」

    グループ指名委員会が2025年度に6回開催され、監査等委員会設置会社への移行を見据えた取締役候補者・サクセッションプランを審議した。報酬委員会も機関設計変更後の報酬制度を審議している。
  2. 2026-05-11AdvancedGovernance

    「To enhance the fairness and transparency of the deliberation process for appointing and dismissing directors and corporate auditors, the Company has established the Group Nomination Committee as an advisory body independent of the Board of Directors. The committee consists of 3 members, all of whom are independent outside directors, to ensure the independence of its deliberations.」

    The operation of the Group Nomination Committee was specified, including its composition of 3 independent outside directors and deliberation on candidates based on a skills matrix. The canonical thread is unchanged.
  3. FY2025AdvancedAnnual report

    「2024年度は、取締役候補者やサクセッションプラン等について審議を行い、取締役会への答申内容を決定いたしました。」

    グループ指名委員会が2024年度に4回開催され、取締役候補者やサクセッションプラン等を審議した活動実績を記載した。
  4. FY2024AdvancedAnnual report

    「2023年度は、取締役候補者やサクセッションプラン等について審議を行い、取締役会への答申内容を決定いたしました。」

    グループ指名委員会・グループ報酬委員会について、2023年度の活動実績として各2回開催し、候補者・サクセッションプラン、報酬割合・非財務指標・株式報酬等を審議した。
  5. FY2023First statedAnnual report

    「さらに、役員の指名や報酬についてその審議プロセスの公正性や客観性を高めるため、取締役会の諮問機関としてグループ指名委員会ならびにグループ報酬委員会を設置しております。」

    役員の指名・報酬の審議プロセスの公正性・客観性を高めるための諮問機関を初めて独立テーマとして記載している。
Moved together

"Overseas Business Expansion Focused on Asia" moved the same way as this thread, in the same document, in 3 of its 5 moves.

333333★123456
  1. ★This thread
  2. 1Overseas Business Expansion Focused on Asia3×
  3. 2FY2025 Sales and Profitability Targets and the Vision of a Total Healthcare Company3×
  4. 3CO2 Emissions Reduction and Energy-Saving Targets3×
  5. 4Development and Launch of a Hair Hormone Measurement Kit3×
  6. 5Reviewing the Rationale for Cross-Shareholdings and Selling Them3×
  7. 6Launch of the Dysmenorrhea Treatment DroEthi3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview It last moved in the Governance of 2026-05-11: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.